{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:10:50Z","timestamp":1790439050359,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004955","name":"Austrian Research Promotion Agency","doi-asserted-by":"publisher","award":["867741"],"award-info":[{"award-number":["867741"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P31362-B34"],"award-info":[{"award-number":["P31362-B34"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.neurot.2025.e00690","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:16:55Z","timestamp":1753993015000},"page":"e00690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Montelukast alleviates neuroinflammation and improves motor functions in the line 61 model of Parkinson's disease: An exploratory study"],"prefix":"10.1016","volume":"22","author":[{"given":"Katharina","family":"Strempfl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Mrowetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Sch\u00f6rghofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Altendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Neddens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Flunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Hutter-Paier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe W.","family":"Poupardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Paiement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Zerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Felder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00690_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The Emerging Evidence of the Parkinson Pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.neurot.2025.e00690_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00690_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fnins.2018.00693","article-title":"Emerging Treatment Approaches for Parkinson\u2019s Disease","volume":"12","author":"Stoker","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurot.2025.e00690_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12264-007-0018-x","article-title":"Pathogenesis of Parkinson\u2019s disease: oxidative stress, environmental impact factors and inflammatory processes","volume":"23","author":"Yuan","year":"2007","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.neurot.2025.e00690_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"\u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00690_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fneur.2019.00122","article-title":"Inflammation, Infectious Triggers, and Parkinson\u2019s Disease","volume":"10","author":"Caggiu","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2025.e00690_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00690_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.parkreldis.2020.11.011","article-title":"P Gervais et al. Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging","volume":"82","author":"Lavisse","year":"2021","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1016\/j.neurot.2025.e00690_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3940(94)90508-8","article-title":"M Minami et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients","volume":"180","author":"Mogi","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurot.2025.e00690_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","article-title":"Nagatsu T.Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients","volume":"165","author":"Mogi","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurot.2025.e00690_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.drudis.2018.09.008","article-title":"Aigner L.The leukotriene signaling pathway: a druggable target in Alzheimer\u2019s disease","volume":"24","author":"Michael","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.neurot.2025.e00690_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/biom12030346","article-title":"Leukotriene Signaling as a Target in \u03b1-Synucleinopathies","volume":"12","author":"Strempfl","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.neurot.2025.e00690_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics13010012","article-title":"Improved Bioavailability of Montelukast through a Novel Oral Mucoadhesive Film in Humans and Mice","volume":"13","author":"Michael","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neurot.2025.e00690_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12868-017-0341-8","article-title":"Early start of progressive motor deficits in Line 61 \u03b1-synuclein transgenic mice","volume":"18","author":"Rabl","year":"2017","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.neurot.2025.e00690_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","article-title":"A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSyn (\u201cLine 61\u201d) mice","volume":"9","author":"Chesselet","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00690_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/biostatistics\/kxm030","article-title":"Small-sample estimation of negative binomial dispersion, with applications to SAGE data","volume":"9","author":"Robinson","year":"2008","journal-title":"Biostatistics"},{"key":"10.1016\/j.neurot.2025.e00690_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neurot.2025.e00690_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.neurot.2025.e00690_bib20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"He QY. clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.neurot.2025.e00690_bib21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.neurot.2025.e00690_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13311-022-01338-0","article-title":"A Mouse Model to Test Novel Therapeutics for Parkinson\u2019s Disease: an Update on the Thy1-aSyn (\u201cline 61\u201d) Mice","volume":"20","author":"Richter","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00690_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.mcn.2005.07.017","article-title":"Sgk1, a cell survival response in neurodegenerative diseases","volume":"30","author":"Schoenebeck","year":"2005","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.neurot.2025.e00690_bib24","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013076","article-title":"Seok MJ, et al. SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models","volume":"13","author":"Kwon","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.neurot.2025.e00690_bib25","doi-asserted-by":"crossref","first-page":"1036844","DOI":"10.3389\/fphar.2022.1036844","article-title":"Serum and glucocorticoid-regulated kinase 1: Structure, biological functions, and its inhibitors","volume":"13","author":"Jang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00690_bib26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/WNR.0000000000000740","article-title":"Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson\u2019s disease","volume":"28","author":"Jang","year":"2017","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurot.2025.e00690_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neulet.2018.05.052","article-title":"Effect of montelukast in experimental model of Parkinson\u2019s disease","volume":"682","author":"Nagarajan","year":"2018","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurot.2025.e00690_bib28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","article-title":"Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective","volume":"19","author":"Knecht","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00690_bib29","doi-asserted-by":"crossref","first-page":"921314","DOI":"10.3389\/fcell.2022.921314","article-title":"Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson\u2019s Disease","volume":"10","author":"Sanchez-Mirasierra","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.neurot.2025.e00690_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/cells12040621","article-title":"Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson\u2019s Disease","volume":"12","author":"Kinet","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neurot.2025.e00690_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s13311-020-00836-3","article-title":"The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies","volume":"17","author":"Marschallinger","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00690_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jnr.10231","article-title":"Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters","volume":"68","author":"Rockenstein","year":"2002","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.neurot.2025.e00690_bib33","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","article-title":"Microglia clear neuron-released \u03b1-synuclein via selective autophagy and prevent neurodegeneration","volume":"11","author":"Choi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2025.e00690_bib34","doi-asserted-by":"crossref","first-page":"105086","DOI":"10.1016\/j.nbd.2020.105086","volume":"146","author":"Kumar","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00690_bib35","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.4103\/1673-5374.259608","article-title":"Inducing \u03b1-synuclein compaction: a new strategy for inhibiting \u03b1-synuclein aggregation?","volume":"14","author":"Pinheiro","year":"2019","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.neurot.2025.e00690_bib37","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00690_bib38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12974-020-01888-0","article-title":"Neuroinflammation is associated with infiltration of T cells in Lewy body disease and \u03b1-synuclein transgenic models","volume":"17","author":"Iba","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurot.2025.e00690_bib39","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/brain\/aww238","article-title":"A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease","volume":"139","author":"Wrasidlo","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00690_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12974-015-0320-x","article-title":"Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson\u2019s disease","volume":"12","author":"Valera","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurot.2025.e00690_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12974-021-02309-6","article-title":"The semantics of microglia activation: neuroinflammation, homeostasis, and stress","volume":"18","author":"Woodburn","year":"2021","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurot.2025.e00690_bib42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.expneurol.2012.06.025","article-title":"Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein","volume":"237","author":"Watson","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurot.2025.e00690_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22052782","article-title":"The leukotriene receptor antagonist montelukast attenuates neuroinflammation and affects cognition in transgenic 5xfad mice","volume":"22","author":"Michael","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.neurot.2025.e00690_bib44","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1523\/JNEUROSCI.5610-12.2013","article-title":"MHCII is required for \u03b1-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration","volume":"33","author":"Harms","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurot.2025.e00690_bib45","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1152\/physrev.00050.2005","article-title":"(Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms","volume":"86","author":"Lang","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.neurot.2025.e00690_bib46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/syn.10307","article-title":"Gene expression profiling in the midbrain of striatal 6-hydroxydopamine-injected mice","volume":"51","author":"Iwata","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.neurot.2025.e00690_bib47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1460-9568.2005.03859.x","article-title":"sgk1, a member of an RNA cluster associated with cell death in a model of Parkinson\u2019s disease","volume":"21","author":"Stichel","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neurot.2025.e00690_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuint.2014.05.006","article-title":"Montelukast rescues primary neurons against A\u03b21-42-induced toxicity through inhibiting CysLT1R-mediated NF-\u03baB signaling","volume":"75","author":"Lai","year":"2014","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.neurot.2025.e00690_bib49","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/nan.12408","article-title":"Age-associated changes in the blood-brain barrier: comparative studies in human and mouse","volume":"44","author":"Goodall","year":"2018","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/j.neurot.2025.e00690_bib50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mds.30144","article-title":"Effects of Montelukast on Neuroinflammation in Parkinson\u2019s Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [11C]PBR28 PET","volume":"40","author":"Wallin","year":"2025","journal-title":"Mov Disord"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:01:19Z","timestamp":1777622479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925001680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1878747925001680"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00690","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Montelukast alleviates neuroinflammation and improves motor functions in the line 61 model of Parkinson's disease: An exploratory study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00690"}}